About Carisma Therapeutics
Carisma Therapeutics is a company based in Philadelphia (United States) founded in 2016 by Michael Klichinsky.. Carisma Therapeutics has raised $3.85 million across 5 funding rounds from investors including AbbVie, TPG and Penn Medicine. The company has 46 employees as of December 31, 2024. Carisma Therapeutics offers products and services including CAR-Macrophages. Carisma Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Philadelphia, United States
- Employees 46 as on 31 Dec, 2024
- Founders Michael Klichinsky
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Carisma Therapeutics, Inc.
-
Annual Revenue
$19.63 M31.59as on Dec 31, 2024
-
Net Profit
$-60.48 M30.39as on Dec 31, 2024
-
EBITDA
$-58.83 M26.89as on Dec 31, 2024
-
Total Equity Funding
$3.85 M (USD)
in 5 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Sep 22, 2022
-
Investors
AbbVie
& 14 more
-
Employee Count
46
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Carisma Therapeutics
Carisma Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CARM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Carisma Therapeutics
Carisma Therapeutics offers a comprehensive portfolio of products and services, including CAR-Macrophages. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered cells to target and destroy tumors in cancer patients
Unlock access to complete
Unlock access to complete
Funding Insights of Carisma Therapeutics
Carisma Therapeutics has successfully raised a total of $3.85M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(18 Apr 2017)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Post-IPO - Carisma Therapeutics | Valuation | AbbVie , Wellington Partners |
|
| Jan, 2021 | Amount | Post-IPO - Carisma Therapeutics | Valuation | Symbiosis | |
| Jul, 2019 | Amount | Post-IPO - Carisma Therapeutics | Valuation | AbbVie , Healthcap |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Carisma Therapeutics
Carisma Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, TPG and Penn Medicine. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage therapeutics companies are invested in by MRLV.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on healthcare startups
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Carisma Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Carisma Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Carisma Therapeutics Comparisons
Competitors of Carisma Therapeutics
Carisma Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Carisma Therapeutics
Frequently Asked Questions about Carisma Therapeutics
When was Carisma Therapeutics founded?
Carisma Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Carisma Therapeutics located?
Carisma Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Is Carisma Therapeutics a funded company?
Carisma Therapeutics is a funded company, having raised a total of $3.85M across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $53M, raised on Apr 18, 2017.
How many employees does Carisma Therapeutics have?
As of Dec 31, 2024, the latest employee count at Carisma Therapeutics is 46.
What is the annual revenue of Carisma Therapeutics?
Annual revenue of Carisma Therapeutics is $19.63M as on Dec 31, 2024.
What does Carisma Therapeutics do?
Carisma Therapeutics was founded in 2016 and is based in Philadelphia, United States. Patient-derived macrophages are genetically engineered to produce chimeric antigen receptor macrophages, known as CAR-M, within the biotechnology sector focused on oncology. Solid tumor indications are targeted, such as recurrent ovarian cancer and HER2-overexpressing malignancies. Research and development efforts emphasize innovative cellular therapies for these conditions.
Who are the top competitors of Carisma Therapeutics?
Carisma Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Carisma Therapeutics offer?
Carisma Therapeutics offers CAR-Macrophages.
Is Carisma Therapeutics publicly traded?
Yes, Carisma Therapeutics is publicly traded on NASDAQ under the ticker symbol CARM.
Who are Carisma Therapeutics's investors?
Carisma Therapeutics has 15 investors. Key investors include AbbVie, TPG, Penn Medicine, Livzon Pharmaceutical, and IP Group.
What is Carisma Therapeutics's ticker symbol?
The ticker symbol of Carisma Therapeutics is CARM on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.